CAUNEDO ÁLVAREZ , Ángel

La presencia de varices esofágicas (VE) es una de las complicaciones más frecuentes de la hipertensión portal en los pacientes cirróticos y puede complicarse en el 30% - 40% de los casos con episodios de sangrado gravados con una mortalidad del 15-20%. El diagnóstico precoz de las VE antes del primer episodio de sangrado es esencial, ya que...

Introduction: the primary goal of this study was to com pare gastrointestinal symptom reduction in patients on bismuth-containing quadruple eradication therapy sup plemented with Lactobacillus reuteri strains (DSM 17938 and ATCC PTA 6475) or placebo. Materials and methods: this was a randomized, dou ble-blind, parallel-arm, placebo-controlled...

No description

Objectives: The course of progressive liver damage after achieving sustained virological response (SVR) with direct-acting antivirals (DAAs) remains undetermined. We aimed to determine risk factors associated with the development of liver-related events (LREs) after SVR, focusing on the utility of non-invasive markers. Methods: An...

Introducción y objetivos: la pandemia por el SARS-CoV-2 ha obligado a un cambio sustancial en la atención a los pacien- tes con patologías digestivas, en especial a los pacientes con enfermedad inflamatoria intestinal (EII), por estar tra- tados con fármacos inmunomoduladores. En este sentido, algunas guías nacionales e internacionales han...

Background: Barrett's esophagus (BE) is an acquired disease defined by the presence of intestinal metaplasia with goblet cells in the distal esophagus. The prevalence of BE has increased dramati cally over the last years. Aims: The primary aims of the study were to analyze the char acteristics of BE and esophageal adenocarcinoma (EAC) in a...

Background: vedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and remission rates with vedolizumab. Methods: this was a retrospective study of inflammatory bowel disease (IBD) patients who received vedolizumab between 2016 and 2019. Response and remission rates were analyzed at three,...

No description

No description

No description